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Targeting the translational machinery has emerged as a promising therapeutic 
option for cancer treatment. Cancer cells require elevated protein synthesis and 
exhibit augmented activity to meet the increased metabolic demand. Eukaryotic 
translation initiation factor 4E is necessary for mRNA translation, its availability and 
phosphorylation are regulated by the PI3K/AKT/mTOR and MNK1/2 pathways. The 
phosphorylated form of eIF4E drives the expression of oncogenic proteins including 
those involved in metastasis. In this article, we will review the role of eIF4E in cancer, 
its regulation and discuss the benefit of dual inhibition of upstream pathways. The 
discernible interplay between the MNK and mTOR signaling pathways provides a 
novel therapeutic opportunity to target aggressive migratory cancers through the 
development of hybrid molecules.
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Translation initiation: an overview
Gene expression is regulated at both the tran-
scriptional and translational levels. Trans-
lational control is critical for maintaining 
protein levels within the cell and achieving 
homeostasis. The majority of mRNA is trans-
lated by the cap-dependent mechanism. This 
is primarily regulated at the level of the initi-
ation phase and involves eukaryotic initiation 
factors and accessory proteins (summarized 
in Figure 1 and reviewed in [4]). Initiation 
factors coordinate vital checkpoints during 
this process and determine both whether a 
specific mRNA is translated and the rate of 
its translation, therefore, contributing to the 
total abundance of specific protein within the 
cell [1].
Translation initiation begins when the 
eIF2–GTP complex binds to the methionyl-
transfer RNA, forming a ternary complex 
that associates with the 40S ribosomal sub-
unit. Additional factors such as eIF5, eIF3, 
eIF1 and eIF1A promote ternary complex 
binding, leading to the construction of the 
43S preinitiation complex. eIF4E, eIF4G 
and eIF4A, also known as the cap-binding 
complex, bind to the m7GTP cap structure at 
the 5′end of the mRNA.
eIF4E recognizes the 5′cap necessary for 
the start of cap-dependent translation ini-
tiation. The structure of eIF4E resembles a 
cupped hand; the concave surface of eIF4E 
binds to the cap and the convex surface inter-
acts with eIF4G [2,3]. The presence of the cap 
structure on eukaryotic mRNA facilitates 
the recruitment of eukaryotic initiation fac-
tors to allow ribosome binding and initiation 
at the correct start site [2]. eIF4G functions 
as a scaffold protein, necessary for the coor-
dinated attachment of translation initiation 
machinery and the ribosome to the 5′end of 
the mRNA [4]. It is a multidomain phospho-
protein that contains binding sites for eIF4E, 
eIF4A, MNK1/2 and PABP [5].
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Figure 1. Eukaryotic cap-dependent translation initiation (see facing page). Eukaryotic initiation factors (eIFs) 
such as eIF1, eIF1A and eIF3 form a 43S pre-initiation complex (PIC), together with the ternary complex (eIF2-
Met-tRNA-GTP), and the 40S subunit. After binding of the ternary complex to the 40S subunit, eIF5 interacts with 
eIF2. The mRNA is activated by the binding of the eIF4F complex (eIF4A, eIF4E and eIF4G) to the cap and PABP to 
the poly(A) tail, circularising the mRNA. The interaction of eIF3/ eIF5 with eIF4G facilitates the binding of the 43S 
PIC near the cap, forming the 48S initiation complex. This 48S initiation complex scans the 5’leader for the AUG 
codon in an ATP-dependent reaction, partial hydrolysis of eIF2-GTP to eIF2-GDP also occurs. Upon start codon 
recognition, eIF1/ eIF1A dissociates, allowing the release of eIF2-GDP +Pi. The joining of the 60S ribosomal subunit 
is promoted by eIF5B, along with the release of other eIFs to yield the final 80S initiation complex and translation 
can then begin. eIF2B, a guanine nucleotide exchange factor, converts the inactive eIF2-GDP to the active eIF2-GTP 
allowing the ternary complex to be reformed.
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Circularization of the mRNA occurs when eIF4G 
binds to PABP, bringing together the 5′ and 3′ ends 
of the mRNA, creating the 48S preinitiation complex. 
Upon recognition of the correct start codon by ribo-
somal scanning, the eIF2–GTP complex undergoes 
hydrolysis, triggering its release from the 48S complex 
along with other eIFs. The dissociation of these fac-
tors allows the binding of the 60S ribosomal subunit 
and the formation of the 80S ribosomal complex. The 
process of peptide bond synthesis can then begin [4,6].
eIF4E & its role in cancer
eIF4E is a critical component of the eIF4F complex 
and the level of eIF4E expression is an important deter-
minant in the translation of mRNAs [7]. Although 
translation initiation is considered to be the rate-
limiting step of protein synthesis and the primary level 
of modulation, recent work has found that substantial 
regulation also occurs at the elongation stage [8]. Cellu-
lar mRNAs differ in the amount of eIF4E required for 
their translation, homeostasis is achieved by maintain-
ing the translation of essential mRNAs and limiting 
the translation of proto-oncogenes. eIF4E is a general 
translation factor but has the potential to selectively 
enhance the translation of mRNAs that leads to the 
production of malignancy-associated proteins [9]. The 
generation of an eIF4E-haplo-insufficient mouse has 
challenged the dogma that eIF4E dose is limiting for 
normal development. Truitt et al. found that a 50% 
reduction in eIF4E expression was compatible with 
regular development and global protein synthesis, 
revealing that eIF4E is present at levels exceeding those 
required for normal translational control. Interest-
ingly, these mice were physiologically normal but resis-
tant to neoplastic transformation. eIF4E appears to be 
limiting for the expression of oncogenic proteins and 
further enforces the importance of eIF4E in cancer 
development [7,8].
The overexpression of eIF4E leads to an increase 
in the translation of a subset of mRNAs that favors 
oncogenesis, in particular those with highly structured 
5′untranslated regions [10]. Housekeeping mRNAs, 
for example, cytoskeleton proteins, require a low level 
of eIF4E, whereas proto-oncogenic and prosurvival 
proteins such as c-Myc, cyclin D1, Pim-1, survivin, 
Bcl-2, VEGF have a much higher dependency on 
eIF4E for translation [11,12]. These mRNAs are termed 
as ‘weak mRNAs’ and are greatly influenced by an 
increase in eIF4E levels, observed in 30% of human 
cancers [13–15]. The availability of eIF4E is regulated by 
4E-binding proteins, which compete with eIF4G for a 
common surface to bind to eIF4E [4,16,17].
A recent study proposes that the mechanism by 
which eIF4E promotes the translation of specific 
mRNAs is by increasing their cytoplasmic levels and 
therefore the capacity of these mRNAs to associate and 
form the eIF4F complex. eIF4E stimulates the nuclear 
transport of mRNAs housing an eIF4E-sensitivity ele-
ment. Notably, these mRNAs encode proteins associ-
ated with growth and malignancy [18]. For example, 
eIF4E regulates the expression of E3 ubiquitin-protein 
ligase, an important negative regulator of p53. Over-
expression of eIF4E promotes the export of the 
mRNA into the cytoplasm in an MNK1-dependent 
manner [19,20].
The oncogenic potential of eIF4E has been reca-
pitulated both in vitro and in vivo. The phosphoryla-
tion of eIF4E is required for its role in mRNA export 
from the nucleus and cellular transformation [21]. 
Recent studies have found that high levels of eIF4E-P 
coincided with poor clinical outcome in human can-
cers [22–24]. MNK1 and MNK2 are serine/threonine 
protein kinases responsible for the phosphorylation of 
S209 on eIF4E [25]. The phosphorylation of eIF4E cor-
relates with the increase in mesenchymal markers such 
as N-cadherin, fibronectin and vimentin, along with 
the acquisition of invasive properties [26].
It has been observed that overexpression of eIF4E 
leads to the transformation of immortalized murine 
fibroblasts and human epithelial cells [1,27,28]. High 
levels of eIF4E were also shown to promote the aber-
rant expression of tumor-related proteins by positively 
regulating the expression of VEGF in a head and neck 
squamous cell carcinoma cell line (HNSCC). Low 
levels of eIF4E were found to downregulate VEGF 
and matrix metalloproteinases, simultaneously, in 
colon cancer. MMP-2 promotes tumor invasiveness by 
degrading type IV collagen, a vital component of the 
Figure 2. Key components of major signaling pathways affecting protein translation (see facing page). Growth 
factors bind to receptors including Receptor Tyrosine Kinases (RTKs) in the cell membrane, stimulating a cascade 
of signals. The activated RTK is phosphorylated on its tyrosine residues, Grb2 docks the phosphotyrosine residues 
via its SH2 domain and subsequently binds the guanine nucleotide exchange factor, Sos, by its SH3 domains. 
Activated Sos promotes the release of GDP from Ras, enabling the binding of GTP to form Ras-GTP. Activated Ras 
recruits Raf to the plasma membrane, where it phosphorylates and activates MEK1/2, which in turn activates ERK. 
ERK phosphorylates and activates many proteins including MNK1/2 and RSK. In addition, ERK phosphorylates 
and inactivates TSC2. MNK1/2 lie at the convergence point of both the p38MAPK pathway and ERK pathways and 
upon activation, phosphorylate eIF4E. Class I PI3 kinases are activated by RTKs resulting in the conversion of PIP2 
to PIP3, a secondary messenger that is essential for AKT translocation to the plasma membrane. The level of PIP3 
is negatively regulated by the tumour suppressor, PTEN. AKT is partially activated by PDK1 and becomes fully 
activated upon phosphorylation at Ser473, a process that can be catalysed by multiple proteins. mTOR forms two 
distinct multiprotein complexes, mTORC1 and mTORC2. In response to stimulation, activated AKT phosphorylates 
and inactivates the TSC1-TSC2 complex, which allows Rheb-GTP to activate mTORC1 on the lysosome. Activated 
mTORC1 stimulates protein translation by phosphorylating 4E-BP1 on several residues, releasing eIF4E allowing 
it to participate in translation initiation. In addition to phosphorylating other translational targets, mTORC1 also 
phosphorylates p70S6 kinase (p70S6K), which becomes fully activated following PDK1-mediated phosphorylation. 
p70S6K targets a number of proteins that control protein translation, including ribosomal protein S6, eIF4B and 
pdcd4. Low glucose levels and hypoxic conditions result in high AMP levels and lead to AMPK activation and 
subsequent mTORC1 inhibition. mTORC2 promotes cell survival through the phosphorylation of AKT on serine 473.
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basement membrane. The increase in expression fre-
quency of eIF4E, VEGF-C, E-cadherin and MMP-2 
was associated with the depth of tumor invasion, 
lymph node metastasis and clinical stage in colorectal 
cancer [29].
Deregulation of mRNA translation can result 
from the overactivation of various upstream kinases 
such as PI3K or AKT, along with the inactivation of 
tumor suppressors, phosphatase and tensin homo-
log (PTEN), tuberous sclerosis complex 1 (TSC1) or 
tuberous sclerosis complex 2 (TSC2). eIF4E acts at a 
convergence point of two important signaling path-
ways in the cell and these upstream mutations can lead 
to the translation of a subset of oncogenic mRNAs [30]. 
This evidence highlights the importance of eIF4E in 
metastasis.
Metastasis of cancer cells and the formation of sec-
ondary tumors are extremely problematic in the clinic, 
accounting for approximately 90% of human cancer 
deaths [31]. Cancer cells require specific and rapid gene 
expression to invoke this invasive phenotype, which 
has the capacity to bypass tissue barriers, intravasate 
into the bloodstream and seed at distal secondary 
sites [1]. Studies have found initiation factors at sites 
of active translation near the leading edge of migrat-
ing fibroblasts. This suggests a mechanism for spatial 
translational control that could be exploited by cancer 
cells during metastasis [32].
Cellular migration is initiated by the integration 
of signals derived from extracellular cues, interac-
tions with the extracellular matrix and contact with 
adjacent cells. Migration begins when cells polarize 
by rearrangement of their actin cytoskeleton, a pro-
cess driven by the action of Rho GTPases [33]. Cells 
extend cellular membrane protrusions, comprising 
broad lamellipodia or spike-like filopodia toward the 
external attractant [34]. These protrusions are stabi-
lized by focal adhesions that link the actin filaments to 
ECM proteins [35].
Experimental evidence has shown that repression of 
eIF4E effectively prevented cell migration in MDA-
MB-231 cells and also sensitized these cells to chemo-
therapy [36]. Disrupting cellular migration is a promising 
therapeutic option for the treatment of cancer [37].
MAPK-interacting kinases
MAPK-interacting kinase 1 is a serine/threonine pro-
tein kinase that lies downstream of both p38MAPK 
and ERK pathways (Figure 2), which is often subject to 
upregulation in tumor cells [9]. These upstream kinases 
activate mouse MNK1 via phosphorylation on Thr 
197/202 [21]. Recent work shows that MNK1 can also 
be phosphorylated by p90 ribosomal protein S6 kinase 
(p90rsk), in a mechanism that confers trastuzumab 
resistance in HER-2 positive breast cancers [38]. The 
MNKs associate with the C-terminus of eIF4G, a vital 
interaction that brings the kinase into close enough 
proximity to phosphorylate eIF4E on Ser209 [5,39]. 
This phosphorylation enhances translation of specific 
mRNAs involved in cell survival [25]. Recent findings 
in a mouse lymphoma model demonstrate that the 
phosphorylated form of eIF4E is required for the trans-
lation of a subset of mRNAs that oppose apoptosis 
and favor tumorigenesis [13,21,30,40–42]. The role of the 
MNKs has been linked to the pathogenesis of many 
cancers [43,44]. PAK2 can interfere with the MNK1/2-
eIF4G interaction by phosphorylating the MNKs 
on specific threonine and serine residues resulting in 
decreased affinity for eIF4G [21].
There are four human MNK isoforms; each MNK 
gene produces both a long isoform and a short isoform 
through variation in splicing [45,46]. The N-termini 
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of all four isoforms are similar; each one containing 
a nuclear localization signal and an eIF4G-binding 
site. The central region houses a kinase domain [9]. 
The C-terminal region of the isoforms differs; the lon-
ger isoforms (Mnk1a and Mnk2a) contain a MAPK 
binding site, which is lacking in the shorter isoforms 
(Mnk1b and Mnk2b) [45,46]. The MNK1a MAPK-
binding domain interacts with both P38MAPK 
and ERK1/2, whereas the MNK2a MAPK-binding 
domain only binds to ERK1/2. This variation is 
reflected in a single amino acid change in the MAPK-
binding site and determines the difference observed 
in their regulation [47]. MNK1a has low basal activ-
ity, and is activated and tightly regulated by ERK and 
p38 kinases in response to mitogens and stress [25,48]. 
MNK2 displays high basal activity and is predomi-
nantly regulated by ERK1/2, although MNK2a is 
regulated by mTORC1 through at least one site in its 
C-terminal region [49,50].
There is speculation as to why mammalian cells 
possess two kinases that perform the same func-
tion but show a variation in basal activity. Data 
show that changes in the phosphorylation status of 
eIF4E in response to growth factors and stress are 
MNK1-dependent.
MNK2 is therefore postulated to maintain a basal 
level of eIF4E phosphorylation under conditions of 
starvation, where MNK1 is inactive, and ensure the 
synthesis of housekeeping proteins [47].
The subcellular location of MNK isoforms like-
wise differs, MNK1a contains a nuclear export sig-
nal allowing its transport to the cytoplasm. MNK1b 
lacks a nuclear export signal, and is localized both 
in the nucleus and cytoplasm, whereas MNK2a 
and MNK2b are predominantly nuclear [19,51]. Both 
MNK1 and MNK2 mRNAs have been found ubiq-
uitously expressed in a variety of tissues by northern 
blot analysis. Fan et al. recently observed a consider-
ably higher percentage of active phospho-MNK in 
astrocytomas, further endorsing the role of active 
MNK in cancer [47,52]. High levels of phosphorylated 
MNK1 are also observed in HER-2 positive breast 
cancer and in glioblastoma multiforme primary 
tumors. Silencing of MNK1 through the infection 
of a U87MG glioma cell line with a small hairpin 
RNA attenuated eIF4E phosphorylation and reduced 
proliferation [38,53].
MNK1/2 present an attractive potential therapeu-
tic target as they act at the convergence point of two 
critical signaling pathways viz; p38MAPK and ERK. 
The MNK1/2 substrate, eIF4E, is also regulated by the 
mTORC1 pathway, which is activated in about 70% 
of cancers [9,21,30,54]. Mice with a targeted deletion of 
MNK1 and MNK2 exhibit total abolishment of eIF4E 
phosphorylation and do not display developmental or 
reproductive defects [21,41]. Additionally, knock-in 
mice expressing a mutant form of eIF4E (S209A) are 
unable to be phosphorylated by MNK1/2 and show 
resistance to neoplastic transformation by C-myc, con-
stitutively active Ras and PTEN loss-induced prostate 
cancer. These mice also exhibit a reduction in vascular 
endothelial growth factor (VEGF) and matrix metal-
loprotease 3 (MMP3), associated with tumour inva-
siveness [40]. Clinical development of MNK inhibitors 
may provide a means to selectively target cancer cells, 
as MNKs are dispensable for normal development [55]. 
The treatment of acute myeloid leukaemia (AML) cell 
lines with MNK inhibitor, cercosporamide (Figure 4C) 
resulted in suppression of MNK kinase activity and 
leukemic progenitor cell growth. In addition, anti-
leukemic effects were amplified when cercosporamide 
was used in conjunction with mTORC1/2 inhibitor, 
rapamycin (Figure 4A) [56]. Recent findings found that 
MNK kinases act as negative feedback regulators in 
response to chemotherapy and hence, contribute to 
chemoresistance. The level of eIF4E-P significantly 
increased in cancer patients during treatment with 
doxorubicin and cyclophosphamide, the standard 
treatment for advanced stage breast cancer. The siRNA 
knockdown or pharmacologic inhibition of MNK1/2 
was found to enhance the chemotherapeutic response 
in both AML and advanced stage breast cancer cell 
lines [24,56].
The crystal structures of MNK1 and MNK2 are 
available in the DFD-out (Asp-Phe-Asp) conforma-
tion (Figure 3). Their catalytic domains share 78% 
sequence identity and the active sites are highly 
conserved [25,57]. MNK1 and MNK2 display the 
canonical bilobal arrangement of the ATP-binding 
cleft sandwiched in between the C-terminal and 
N-terminal lobes. The C-terminal lobe is predomi-
nantly α-helical and is composed of the activation 
segment, the P-loop and the catalytic loop; elements 
required for substrate binding and phosphate trans-
fer. Kinase activation occurs when the activation 
loop is phosphorylated, resulting in a conformational 
change. The P-loop enables the optimal alignment 
of the phosphoryl groups of ATP, while the catalytic 
loop encompasses highly conserved residues vital for 
phosphotransfer. The N-terminal lobe comprises five 
β-strands and the regulatory αC-helix. The αC-helix 
is misaligned in inactive kinases and its correct align-
ment is required for ATP binding, and hence kinase 
activity [58,59].
The conserved DFD motif marks the beginning of 
the activation loop [58,60]. The DFD motif (Asp191-
Phe192-Asp193 in MNK1 and Asp226-Phe227-
Asp228 in MNK2) has less affinity for ATP than the 
Figure 3. Apo-form of Mnk1 in inactive conformation DFD-Out conformation (PDB ID: 2HW6). Structural elements 
colored accordingly: N-terminal lobe (purple), C-terminal lobe (cyan), αC-helix (pink), hinge region (green), 
catalytic loop (orange), DFD-motif (grey), activation segment (red) and p-loop (gold). Auto-inhibition due to 
Phe230 in the activation segment pushing out Phe192 away from DFD towards the ATP binding site, obstructing 
the ATP binding pocket. Molecular graphics and analyses were performed with the UCSF Chimera package [123].
DFD: Asp-Phe-Asp; UCSF: University of California, CA, USA.  
For color figures see www.future-science.com/doi/full/10.4155/fmc-2017-0062
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equivalent DFG motif present in other kinases. This 
is due to a 180° rotation relative to the DFG motif, 
which locks the kinase in the DFD-out conformation. 
This unique structure coupled with specific regions of 
the catalytic domain (insertions 1-3) distinguishes the 
Mnks from other kinases and provide an opportunity 
to design specific Mnk inhibitors [9,61].
mTOR
Mammalian target of rapamycin is a Ser/Thr protein 
kinase complex that lies downstream in the PI3K/
AKT signaling pathway. mTOR, known as the master 
regulator of the cell, responds to signals from extra-
cellular stimuli, amino acid availability, oxygen and 
energy status of the cell. Signaling is stimulated by 
growth factors and mitogens.
mTOR belongs to the phosphatidylinositol 3-kinase 
family, and forms two multiprotein complexes; mTOR-
C1and mTORC2. The complexes both contain mTOR 
kinase but differ in the associated regulatory proteins. 
mTORC1 is defined by the regulatory-associated 
protein of mTOR (RAPTOR) whereas mTORC2 is 
defined by the rapamycin-insensitive companion of 
mTOR (RICTOR; Figure 2) [62].
mTORC1 is activated by multiple growth factors, 
insulin and nutrients through the PI3K/AKT pathway 
and has a central role in stimulating protein synthe-
sis [63,64]. The interaction between eIF4G and eIF4E in 
the eIF4F complex is inhibited by 4E-binding proteins. 
4E-BP1 competes with eIF4G for a shared binding site 
on eIF4E. The interaction strength of 4E-BP1 bind-
ing to eIF4E depends on the phosphorylation status 
of 4E-BP1 [65]. Hypo-phosphorylated 4E-BP1 binds 
strongly to eIF4E whereas hyper-phosphorylated 
4E-BP1 weakens its interaction with eIF4E [4,16,66]. 
4E-BP1 contains at least seven sites of phosphory-
lation, of which four are known to be regulated by 
mTORC1 and associated signaling pathways [66]. Acti-
vated mTORC1 remains at the mRNA 5′cap where 
it can promote cap-dependent mRNA translation by 
phosphorylating and inactivating 4E-BP1, activat-
ing p70S6K and increasing overall protein synthesis 
by stimulating rRNA transcription and ribosome bio-
genesis [67,68]. mTORC1 also has a prominent role in 
lipid synthesis, required for the generation of cellular 
membrane during proliferation [67]. Cancer cells often 
hijack the PI3K/AKT/mTOR pathway in order to meet 
the demands of increased growth rate, as observed in 
patients with acute myeloid leukemia [69–71].
mTORC1 integrates signals from the cellular envi-
ronment with the translational apparatus by phos-
phorylating p70S6K; a subsequent phosphorylation 
by PDK1 leads to its full activation and its release 
from eIF3 [69,72]. Active p70S6K subsequently phos-
phorylates ribosome protein S6, eIF4G, eIF4B, pdcd4 
and fragile X mental retardation protein, an mRNA-
binding protein [73,74]. mTORC1 also responds to 
the energy status of the cell, a decrease in the ATP/
AMP ratio activates AMPK, which suppresses 
mTORC1. Hypoxic conditions induce the expression 
Figure 4. Inhibitors. (A) Allosteric inhibitors of mTOR, (B) catalytic site inhibitors of mTOR, (C) catalytic site inhibitors of Mnk1/2 and 
(D) hybrid agents.
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of protein regulated in development and DNA dam-
age response 1 (REDD1), a protein that modulates 
TSC2 activity, leading to inhibition of mTORC1 [64]. 
mTORC1 is a negative regulator of autophagy, an 
important cellular process in which damaged organ-
elles and intracellular pathogens are degraded inside 
lysosomes [69]. It is stimulated by branched chain 
amino acids through the RAS-related GTP-binding 
proteins, (RAG) family of GTPases, which recruit 
mTORC1 to lysosomes where it becomes activated by 
Rheb. mTORC1 phosphorylates unc-51 like autoph-
agy activated kinase (ULK1) and its positive regulator, 
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autophagy-related protein 13 (ATG13), inhibiting 
autophagosome formation [67,75,76]. Signaling path-
ways involving mTORC1 are complex, and there 
are many negative loops which add a further level of 
regulation. One such loop involves the phosphoryla-
tion of insulin receptor substrate 1, either directly 
by activated mTORC1 or via mTORC1 activated 
p70S6K. This leads to its degradation and results in 
a decrease in PI3K/AKT signaling and subsequently a 
downregulation of mTORC1 activity [75].
The role and regulation of mTORC2 remain 
ambiguous, partly due to the lack of an mTORC2 
selective inhibitor. mTORC2 is thought to be involved 
in cell survival and cell-cycle progression through 
phosphorylation of Ser473 on AKT, and through 
activation of serum- and SGK and PKC [9,62,67,75]. 
Recent advancements, in yeast, using reverse chemi-
cal genetics have allowed specific mTORC2 inhibi-
tion, although an analogous system in mammalian 
cells has yet to be established [77]. Genetic studies 
involving the deletion of the RICTOR subunit, an 
essential scaffold protein, results in mTORC2 disas-
sembly and loss of function. However, unlike acute 
chemical inhibition, genetic studies permit adaption 
to occur, often confounding results. For example, 
phosphorylation of AKT Ser473 was observed in 
RICTOR-deficient cells. A proposed explanation is 
the adaptation of the cell to the genetic change allow-
ing the phosphorylation of AKT Ser473 by other 
kinases such as DNA-PKCS [78,79].
mTOR & its role in cancer
Inactivating mutations in the tumor suppressor gene, 
PTEN, a phosphatase that antagonizes PI3K func-
tion are a common feature in cancer cells [71]. This 
causes an upregulation of PI3K activity in the cell and 
constitutive stimulation of the PI3K/AKT/mTOR 
pathway [42,80]. Activated mTORC1 has a multitude 
of consequences in cancer development. mTORC1-
dependent phosphorylation of 4E-BP1 causes its 
release from eukaryotic initiation factor 4E. eIF4E 
forms part of the eIF4F complex (with the helicase 
eIF4A and the scaffold protein, eIF4G) and the level 
of eIF4E expression is a critical determinant in the 
translation of oncogenic mRNAs [7,8]. Ribosome pro-
filing studies reveal that some mTOR translation-
ally regulated mRNAs possess a 5′terminal oligopy-
rimidine tract, also termed as 5′TOP [81,82]. These 
mRNAs include YB1, vimentin, MTA1 and CD44, 
all of which have a significant role in the process of 
metastasis. Hyperactive mTOR signaling has a pro-
found effect on the translational landscape of cancer 
cells by positively regulating this four-gene invasion 
signature [63,83].
A hallmark of cancer cell reprogramming 
is the switch to aerobic glycolysis metabolism. 
Activated mTORC1 increases the transcription and 
translation of hypoxia inducible factor (HIF1α), 
which in turn regulates glycolytic genes, enabling the 
tumor cell to meet the high demands required for sur-
vival and progression [70,84]. There is also evidence that 
both mTORC1 and mTORC2 are implicated in the 
epithelial–mesenchymal transition (EMT) [85]. EMT 
in relation to cancer can be defined as the conversion 
of differentiated epithelial cells into migratory mesen-
chymal cells through the loss of epithelial markers and 
the gain of mesenchymal markers [86]. This is thought 
to occur in part, through the modulation of genes that 
code for proteins associated with cytoskeleton rear-
rangement, such as RhoA, Rac1 and Cdc42 GTPases. 
mTORC1 mediated signaling also plays a role in the 
phosphorylation of focal adhesion proteins and the 
promotion of cell motility [33].
Deregulation of the mTOR pathway is correlated 
with poor clinical outcome and drug resistance [84]. 
There are currently only two US FDA approved mTOR 
inhibitors available for cancer treatment (temsirolimus 
and everolimus). However, both have had limited suc-
cess in the clinic due to the activation of negative feed-
back loops which trigger activation of MNK1. This 
effect of targeted mTORC1 inhibition was confounded 
by a recent study of rapamycin treated myeloma cells, 
which resulted in the increased phosphorylation of 
MNK1 along with its target, eIF4E [21,42]. The mul-
tiplicity of on-target side effects also limits the use of 
rapamycin due to mTORC1’s wide variety of cellular 
functions [87].
Interplay between the mTOR & Mnk/eIF4E 
pathways
There is some evidence for a compensatory feed-
back mechanism linking the AKT/mTOR pathway 
and the MNK/eIF4E pathway. Both pathways are 
required for efficient protein translation and a fine 
balance needs to be achieved for cellular homeo-
stasis. This was reported in both prostate and lung 
cancer, where the downregulation of one pathway 
correlated with the activation of the other, which 
subsequently supported cell proliferation and cancer 
survival [41,42].
This interplay between both MNK and mTOR path-
ways has also been reported clinically. Rapamycin, a 
naturally occurring macrolide, originally purified from 
Streptomyces hygroscopicus was initially used in trans-
plant patients to prevent allograft rejection [22,88,89]. 
Synthetic analogs of rapamycin, such as temsirolimus 
and everolimus have been used to treat cancer patients 
with hyperactive PI3K/AKT/mTOR signaling. 
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Rapamycin and rapalogs are allosteric inhibitors of 
mTORC1, and work by recruiting FKBP-12, an acces-
sory protein, to the FRB domain of mTOR. The for-
mation of this drug–protein complex causes a confor-
mational change in mTORC1, distal from the kinase 
domain, leading to its inhibition [69,90]. Recent struc-
tural studies have further elucidated the mechanism 
by which rapamycin inhibits mTORC1 [91]. Com-
plex feedback loops involving activation of PI3K and 
MAPK signaling have limited the success of mTOR 
inhibitors in the clinic [30,69]. Several studies have 
shown that rapamycin treatment increases the level of 
eIF4E phosphorylation and AKT activation [42,92–94], 
contributing to the development of resistance to 
mTOR inhibitors [95].
Cancer cells have adapted to mTOR inhibition 
by downregulating the expression and translation of 
4E-BPs [96]. Increases in the eIF4E-4E-BP1 ratio, lim-
its the effect of mTOR inhibitors [69]. Chronic mTOR 
inhibition in SW620 colon cancer cells with superior 
catalytic site inhibitors such as AZD8055, resulted in 
an increase in eIF4E expression. This shift in signaling 
promotes cap-dependent translation and appears to be 
more instrumental in cancer progression in comparison 
to S6K signaling [64,75,83].
Acute treatment with active site inhibitors of mTOR 
induces autophagy, which is a double-edged sword 
in relation to tumor development and can be both 
antitumorigenic or protumorigenic depending on the 
stimulus [67,69]. Autophagy can induce a prosurvival 
phenotype in cancer cells through maintaining cellular 
energy levels in conditions of starvation and stress by 
degrading intracellular organelles [97].
Targeting eIF4E signaling downstream of mTOR 
by inhibiting MNK kinases may prevent feedback 
initiation [30]. Simultaneous inhibition of MNK1/2 
kinase and mTORC1 suppressed cell-cycle progression 
and blocked proliferation in both PC-3 and glioblas-
toma cell lines [41,42]. This effect was increasingly pro-
nounced when inhibitors were added in combination 
as opposed to being employed as a monotherapy, indi-
cating the importance of dual abrogation of such path-
ways [41,42]. A recent study also found that the MNK 
inhibitor, CGP57380, attenuates RAD001-activated 
eIF4E phosphorylation in non-small-cell lung cancer 
cells. Such a combination of inhibitors augmented the 
antitumor response by inhibiting cell proliferation and 
inducing apoptosis [98].
Therapeutic targeting & the concept of 
hybrid inhibitors
Cancer is notoriously heterogeneous and difficult 
to treat. Each cell constitutes a different genetic 
make-up, due to variations in the pattern of active 
oncogenes and inactive tumor suppressors. A given 
drug may successfully eliminate cells harbor-
ing a specific mutation, however, cells driven by 
alternative pathways will survive [22]. Even clonally 
derived tumor cells exhibit variation in drug resis-
tance [99]. The complexity of cellular signaling 
means that the traditional single treatment approach 
is often ineffective, and inhibition of multiple tar-
gets is required to stay one step ahead of the tumor 
cell [80,100,101]. Advances in personalized medicine 
and genomic screening have enabled the identifica-
tion of specific mutations in an individual patient. 
This enhanced knowledge can then be used to tai-
lor treatment to target oncogene addictions, exploit 
synthetic lethalities and establish the most suitable 
combination of therapies [99,102].
The failure to respond to treatment results from a 
combination of host factors and genetic alterations in 
the cancer cell. These host factors can include poor 
absorption, rapid metabolism and excretion, along 
with the inability to deliver the drug to the site of the 
tumor. Bulky solid tumors and high molecular weight 
compounds often account for low penetrance. Elderly 
patients frequently exhibit poor tolerance, which 
leads to sub-optimal dosing and the development of 
resistance, allowing the cancer to survive [99].
Currently, the only FDA approved approach for 
the inhibition of the PI3K/AKT/mTOR pathway is 
through the use of mTOR allosteric inhibitors, evero-
limus and temsirolimus (see Figure 4). These rapalogs 
have been effective in the treatment of renal cell car-
cinoma but have significant disadvantages due to their 
feedback activation of AKT [69,84,103]. A new generation 
of mTOR catalytic site inhibitors holds much promise 
due to their potent inhibition of both mTORC1 and 
mTORC2, thus attenuating the feedback mechanism 
involving AKT phosphorylation [104]. These inhibi-
tors are ATP analogs that contain a heterocyclic struc-
ture to exploit the adenine-binding pocket and can 
form hydrogen bonds with the hinge region of the 
kinase [105]. Type II inhibitors introduce additional 
specificity by binding not only the ATP pocket but 
also an adjacent allosteric pocket [106,107]. The recently 
solved crystal structure of the mTOR kinase domain 
in complex with ATP-competitive inhibitor, PP242, 
will no doubt facilitate the design and synthesis of fur-
ther catalytic mTOR inhibitors [108,109]. It is important 
to note that at this time there are no FDA approved 
drugs which specifically act on MNK kinases, and 
little progress has been made since the discovery of 
CGP57380, which exhibits low micromolar MNK 
inhibition [110]. Cercosporamide, a natural antifungal 
agent, was found to be a potent inhibitor of MNK1/2, 
in the nanomolar range. However, its broad-spectrum 
Figure 5. MNKI-19 and PP242 combination results in a synergistic cytotoxicity and has led to the development 
of a novel hybrid agent. (A & B) Cell viability assay in MRC5 cells and T98G cells, respectively. Cells were treated 
with DMSO (1), MNKI-19 1 μM (2), PP242 1 μM (3) and a combination of MNKI-19/PP242 1 μM each (4) for 24 h. 
Optimal concentrations of Mnk inhibitor, MNKI-19, were determined in prior experiments in accordance with 
Teo et al. (2015). Screening data also showed no effect of MNKI-19 on CDK2A or CDK9T1 kinases [110]. Cell viability 
was determined by CellTiter Blue assay. Data are presented as the means ± SD, n = 3. (C) Western blot analysis for 
the expression of eIF4E-P, 4EBP1-P and rpS6 P-240/ 244 in MRC5 cells treated with DMSO (1), MNKI-19 (2), PP242 
(3) and a combination of MNKI-19/ PP242 (4), as in Panel A for 24 hr, [E. Lineham, Unpublished data]. (D) Structure of 
MNKI-19.
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effects limit its uses as an effective treatment as it also 
inhibits a number of other kinases, including JAK3, 
GSK3β, ALK4 and Pim1 at low micromolar potency 
(see Figure 4) [9,111,112].
The need for a multitargeted treatment regime has 
led to complex ‘drug cocktails’ being administered 
to patients. For example, a chemotherapy protocol 
known as ‘CHOP’ is used to treat non-Hodgkin 
lymphoma. This combination therapy consists of 
cyclophosphamide (immunosuppressant), hydroxy-
daunomycin (DNA intercalator), oncovin (anti-
mitotic) and prednisolone (immunosuppressant ste-
roid) [113]. Although often well-tolerated, combination 
therapies can have several drawbacks. These include 
poor patient compliance, drug–drug interactions and 
potentially severe side effects. The coformulation of 
multiple drugs into a single dosage improves patient 
compliance by simplifying dosing regiments, however, 
complex pharmacokinetic (PK) and pharmaco dynamic 
(PD) relationships occur through the variation in 
metabolism rate among patients [101].
The focus has now shifted to the idea of a single 
chemical entity that comprises elements capable of 
inhibiting multiple biological targets. The complex 
nature of cancer has led to the concept of hybrid 
drugs, which act on multiple targets with the need 
to deliver more than one drug concurrently. Combi-
nation therapy involves the linking of two selected 
pharmacophores that act against different therapeu-
tic intracellular targets simultaneously. This multihit 
hypothesis results in a synergistic affect and makes 
drug resistance less likely [41].
Hybrid drugs can be synthesized by ‘blending’ 
two pharmacophores with similar sub-structures 
together or by joining the separate compounds via 
noncleavable or cleavable linkers [102]. In the latter 
approach, using a labile linker such as an ester can 
result in the release of the two drugs when cleaved 
by plasma esterases [99]. The rationale behind the 
development of hybrid drugs is the simultaneous 
presence of chemical entities in the cell, which may 
act in a synergistic manner to augment potency and 
reduce side effects [101,102,114]. This is in contrast to 
the administration of individual drugs that will inevi-
tably be delivered to the target site at different rates 
and efficacies. Hybrid compounds can often display 
improved bioavailability and present more predict-
able pharmacokinetic and pharmacodynamic profiles 
in comparison to individual agents [102,114].
There are limitations with hybrid drugs, as most 
of these compounds will violate both Veber et al. 
and Lipinksi’s rules governing oral bioavailability 
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in particular by exceeding molecular weight, polar 
surface area and logP values [115–117]. This means 
that administration may be limited to the IV or topi-
cal route, although poor aqueous solubility may be 
improved by using linkers that impart hydrophilicity, 
such as polyethylene glycol linkers [99]. The chemical 
stability of the linker is important in cleavable hybrid 
agents, as it should not be cleaved before reaching 
the target site. Another potential difficulty lies in the 
dosing, if the optimal ratio between conjugates is not 
1:1 [102].
Currently, estramustine may be considered to 
be the only FDA-approved hybrid in the clinic and 
is used to treat advanced stage prostate cancer [99]. 
Nevertheless, there is a huge amount of excitement sur-
rounding hybrid drugs and researchers are continuing 
to make progress with the development of novel agents. 
For example, HDAC inhibitors have been successful in 
the treatment of hematological malignancies, although 
have had limited therapeutic effect in solid tumors. 
Vorinostat recently failed as a monotherapy in a meta-
static breast cancer clinical trial [102,118]. However, 
synergistic effects have been observed when HDAC 
inhibitors have been used in combination with other 
drugs, including a significant decrease in cell viability 
when used in conjunction with Sorafenib, a dual action 
VEGFR/PDGFR and RAF kinase inhibitor [119,120]. 
This has prompted the development of HDAC inhibi-
tor containing hybrid agents, for example, a recently 
synthesized dual HDAC/VEGFR2 inhibitor [114]. 
Another promising agent, CUDC-101, developed by 
Curis, was found to simultaneously inhibit HDAC 
class I/II, EGFR and HER2 and exhibited antiprolif-
erative effects in vitro and growth inhibition in vari-
ous cancer xenograft models [121]. It is currently being 
investigated in combination with radiation and other 
agents such as cisplatin in HSNCC [122].
The synthesis of a dual action MNK/mTOR hybrid 
agent may be an effective option for inhibiting eIF4E 
phosphorylation and warrants further investigation. 
Preliminary experiments detailed in Figure 5, demon-
strate that dual inhibition of MNK and mTOR led to 
a significant reduction in cell viability in both MRC5 
fibroblast and T98G glioblastoma cell lines. Further 
analysis by western blotting shows potent inhibition 
of downstream targets; eIF4E-P, 4EBP1-P and rpS6 
P-240/242 when both the MNK inhibitor, MNKI-
19, and an mTOR inhibitor, PP242, were used in a 
1:1 mixture. These data, in agreement with the litera-
ture, support the potential benefit of linking the two 
inhibitors as a single chemical entity. The develop-
ment of dual action hybrids, be they joined by a ‘per-
manent’ or cleavable linker, is a current theme in our 
laboratory and results will be published in due course.
Conclusion & future perspective
The overexpression and deregulation of translation 
factors, in particular, eIF4E, have been linked to the 
pathogenesis of many aggressive human cancers. The 
phosphorylation of eIF4E by MNK1/2 kinase corre-
lates with invasive and metastatic behavior, through 
the preferential translation of mitogenic proteins. 
eIF4E expression has also found to reflect the level of 
mesenchymal markers.
Experimental evidence has proven that the availabil-
ity of eIF4E for translation can be repressed through 
the inhibition of mTORC1. Additionally, silencing 
MNK1/2 attenuates eIF4E phosphorylation and 
reduces the translation of mRNAs involved in metas-
tasis. However, the independent suppression of either 
pathway induces complex feedback loops that stimu-
late activation of alternative pathways. eIF4E lies at 
the convergence point of both the mTOR and MNK/
eIF4E pathways, which provides an opportunity for 
dual targeting.
Personalized, multitargeted therapy is becoming 
increasingly popular. Hybrid molecules incorporate 
several moieties that bind to and inhibit different bio-
logical targets, delivering a double-blow to cells. In 
this regard, the complementary mTOR and MNK 
pathways are a promising target for such hybrid agents 
in the treatment of aggressive migratory cancers. 
Advances in the knowledge of PI3K/AKT/mTOR and 
MNK/eIF4E pathways in oncogenesis will contribute 
to the understanding of drug resistance. Furthermore, 
the expanding array of structural biology knowledge 
will aid rational drug design and enhance the drug 
discovery effort.
The benefits of hybrid drugs can clearly be observed; 
however, it is still a growing area of research and further 
development of these agents is required.
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